Australia Diabetes Care Drugs And Devices Market Size and Share
Market Overview
| Study Period | 2020 - 2031 |
|---|---|
| Forecast Data Period | 2026 - 2031 |
| Historical Data Period | 2020 - 2024 |
| Growth Rate | 9.08 % |
| Market Concentration | Medium |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. | |
Australia Diabetes Care Drugs And Devices Market Analysis by Mordor Intelligence
The Australia Diabetes Care Drugs And Devices Market size is expected to register a CAGR of 9.08% during the forecast period.
The COVID-19 outbreak has accelerated the expansion of the Australian diabetes drug market. People with diabetes infected with COVID-19 can develop high blood sugar levels, irregular blood sugar fluctuations, and diabetic complications. There have been 9,235,681 confirmed COVID-19 cases in Australia since the pandemic began in July 2022, according to the Australian government's Department of Health and Aged Care. The prevalence of diabetes in adults with COVID-19 may be higher than that of patients with type 1 (T1DM) or type 2 (T2DM) diabetes, especially when glycemic control is poor. They are leading to a significant increase in the severity and mortality of cancer. On the other hand, emerging hyperglycemia and diabetes (both T1DM and T2DM) associated with COVID-19 are increasingly recognised and associated with poor prognosis. Patients' blood glucose levels should be checked and maintained regularly to minimize exacerbations, highlighting the importance of drug therapy in diabetes treatment.
Obesity, poor diet, and lack of exercise contribute to the increasing number of newly diagnosed cases of type 1 and 2 diabetes. Rapid increases in the incidence and prevalence of diabetes and healthcare costs in developed countries indicate increased use of diabetes care products. In addition, the rising incidence of diabetes and increasing use of insulin-delivery devices are driving the expansion of the market. Leading manufacturers focus on technological advances and developing improved products to gain significant market share.
Thus, the above factors are expected to drive the market growth over the forecast period.
Note: Market size and forecast figures in this report are generated using Mordor Intelligence’s proprietary estimation framework, updated with the latest available data and insights as of 2026.
Australia Diabetes Care Drugs And Devices Market Trends and Insights
The continuous Glucose Monitoring Segment is Expected to Witness the Highest Growth Rate Over the Forecast Period
Continuous blood glucose monitoring is a popular alternative to commercially available portable finger glucose meters for people with diabetes. Continuous glucose monitoring sensors use glucose oxidase to measure blood sugar levels. Glucose oxidase converts glucose to hydrogen peroxidase, which reacts with platinum in the sensor to send an electrical signal to a transmitter. Various promising glucose sensor technologies are being developed, ranging from traditional electrochemical glucose sensors to new optical and other electrical glucose sensors, positively impacting the market growth.
The National Diabetes Services Scheme (NDSS) is an Australian government initiative. Once the patient is enrolled in their NDSS, they can use the blood glucose monitoring product with a subsidy. Registration with the NDSS is free and open to anyone in Australia who has a Medicare card and is diagnosed with diabetes. Patients and medical team members are required to complete an NDSS registration form. NDSS supplements blood glucose strips. Patients with type 1 diabetes are eligible for subsidized FGM and CGM. In addition, current continuous blood glucose monitors can display blood glucose trends by downloading data or providing real-time images of blood glucose levels through the receiver's display. In addition, current continuous blood glucose monitors can display blood glucose trends by downloading data or providing real-time images of blood glucose levels via the receiver's display. The emergence of new technologies, such as cell phone integration, will likely make continuous blood glucose monitoring devices cheaper, boosting the field. The emergence of new technologies, such as cell phone integration, will likely make continuous blood glucose monitoring devices more affordable, boosting the field.
Rising diabetes prevalence
The diabetic population in Australia is expected to grow by approximately 2.5% during the forecast period. According to Diabetes Australia, diabetes is Australia's fastest-growing chronic disease, rising faster than other chronic diseases such as heart disease and cancer. Approximately 1.9 million Australians have diabetes, including all forms of diagnosed diabetes (about 1.5 million known and registered) and undiagnosed type 2 diabetes (up to 500,000 presumed to be human). The incidence of diabetes in children and adolescents is increasing. Nearly all children and adolescents with diabetes have type 1 diabetes. In addition, the child develops type 2 diabetes when he is young. Children and adolescents with type 1 and type 2 diabetes have unique needs, including care from a multidisciplinary childhood diabetes team, diabetes care, and access to assistive technology.
One of the main goals of diabetes treatment is to maintain blood sugar levels within specific target ranges. This can be achieved through activity, lifestyle, and a balanced diet with diabetes medications. Blood glucose monitoring readings provide the information to determine the optimal diabetes management strategy. Keeping your blood sugar within your target range can reduce your risk of developing diabetes-related complications such as diabetic retinopathy, heart disease, and kidney disease. How often people with diabetes check their blood sugar levels depends on how often they use insulin due to several factors. People with type 2 diabetes who don't use insulin may not need to check their blood sugar regularly. However, systematic self-monitoring for a period may be helpful.
Adolescents are at a higher risk of developing diabetes at an early age due to their younger age and longer duration of diabetes, which reduces the quality of life, shortens life expectancy, and increases social health expenditure. As a result, the demand for antidiabetic drugs and their approval rates are rising, which drives the market. Furthermore, with the growing awareness of people with type 2 diabetes, the need for diabetes drugs and devices is rapidly increasing.
The increasing diabetes prevalence and the above factors will likely drive segment growth over the forecast period.
Competitive Landscape
Manufacturers have constantly innovated to survive in the market. Large companies such as Abbott and Medtronic have made numerous mergers, acquisitions, and partnerships to gain market dominance while adhering to organic growth strategies. The manufacturers of insulin delivery devices are spending a huge amount on the R&D of the devices. For example, Novo Nordisk partnered with Abbott Diabetes Care, which may also assist in enabling insulin statistics to be shared between Novo Nordisk-connected insulin pens and digital fitness equipment well suited to the FreeStyle Libre portfolio of products. Mega Blockbuster Lantus, manufactured with the aid of Sanofi, led the basal insulin field.
Australia Diabetes Care Drugs And Devices Industry Leaders
Medtronics
Roche
NovoNordisk
Sanofi
Omnipod
- *Disclaimer: Major Players sorted in no particular order
Market Opportunities and Future Outlook
Public reimbursement and pricing settings continue to create room for drug and device uptake in Australia. Under the Cheaper Medicines policy package, the Australian Government lowered the maximum PBS co-payment to AUD 25 per prescription from 1 January 2026. On the pipeline-to-access side, PBAC activity around novel therapies is a near-term catalyst, with tirzepatide (Mounjaro) recommended for PBS subsidy for type 2 diabetes at the March 2026 PBAC meeting. This keeps the focus on listing negotiations, patient eligibility criteria, and downstream demand for more intensive glucose monitoring and titration support.
For devices and digital care, the main opportunities center on integrated insulin delivery and monitoring workflows, along with compliant software enablement. The Therapeutic Goods Administration (TGA) continues to refine how software-based medical devices and health self-management software are classified and regulated, and Australia is progressing Unique Device Identification (UDI) implementation timeframes. Together, these factors shape go-to-market plans for connected pens, CGM apps, and automated insulin delivery workflows. Commercial momentum in automated insulin delivery is also visible through Omnipod 5 reaching one year of availability in Australia as of March 2026, which supports broader clinician adoption, NDSS-linked access pathways, and data integration initiatives with connected insulin and monitoring platforms.
Recent Industry Developments
- July 2026: Novo Nordisk's Tresiba is listed as subsidized via the Pharmaceutical Benefits Scheme for Australians aged 1 year and older with type 1 diabetes. The PBS subsidy expands patient access to insulin degludec. This update broadens diabetes care uptake in Australia and reinforces insulin market leadership and pricing leverage in the local market.
- June 2026: Recce Pharmaceuticals has received HREC approval for pivotal Phase 3 trial of RECCE 327 Topical Gel for diabetic foot infections in Australia, extending the study to moderate infection cases. This approval supports the trial in Australia for diabetic foot infection therapy candidate and includes moderate infection patients. It advances a potential new treatment option and could change competitive dynamics in diabetic foot infection management within the report scope.
- January 2026: Medtronic gains US FDA clearance for MiniMed Go smart MDI system, which integrates InPen with Abbott's Instinct sensor. This milestone updates the global insulin delivery and CGM integration landscape. It may affect Australian market players and product strategies.
Research Methodology Framework and Report Scope
Market Definition and Coverage
This market covers the value of medicines and medical devices used in Australia to manage diabetes, including drug therapies and tools used to monitor glucose and deliver insulin in routine care.
Scope exclusions: Diabetes prevention programs, weight loss medicines used without a diabetes indication, and broader hospital diabetes service fees are excluded from this market value.
Segmentation Overview
- Devices
- Monitoring Devices
- Self-monitoring Blood Glucose Devices
- Continuous Blood Glucose Monitoring
- Management Devices
- Insulin Pump
- Insulin Syringes
- Insulin Cartridges
- Disposable Pens
- Monitoring Devices
- Drugs
- Oral Anti-Diabetes Drugs
- Insulin Drugs
- Combination Drugs
- Non-Insulin Injectable Drugs
Data Sources, Market Sizing, and Validation
Desk Research
Desk research is used to anchor the model to real Australia level demand signals and policy context, before any pricing and adoption assumptions are applied. We start with public health prevalence and treatment pathway references, then map them to how therapies and devices are actually supplied and reimbursed.
Common sources include national statistics and health system references such as the Australian Institute of Health and Welfare, the Australian Bureau of Statistics, the Department of Health and Aged Care, NDSS program updates, and PBS related public schedules and publications, alongside peer reviewed clinical guidelines. To translate this into market value, we review company filings, investor presentations, and credible press, and use paid subscriptions for company financials, news and financials, and patent databases selectively to sanity check product cycles and category direction. This list is illustrative and not exhaustive, and many other sources were also used for data collection, validation, and clarification.
Primary Interviews and Surveys
Primary work is used to pressure test adoption, replacement cycles, and realized pricing in the Australian setting, where reimbursement and channel mix can shift after policy updates. We spoke with clinicians, pharmacists, payor informed stakeholders, distributors, and device oriented roles, which helped us close gaps on CGM uptake, insulin delivery mix, and the practical split between hospital and home use.
Distribution of primary research fieldwork respondents
| Company type | Respondent position |
|---|---|
| Top tier: 33% | CXOs: 18% |
| Mid tier: 47% | Functional/Unit leaders: 29% |
| Smaller Players: 20% | Managers: 53% |
Market-Sizing & Forecasting
Sizing starts from a top-down reconstruction of the treated and monitored population in Australia, then moves through therapy and device utilization to reach an annual value. In practice, prevalence and diagnosed pool references are converted into treated cohorts, which are then split by insulin use, non-insulin therapy use, and monitoring intensity before value is calculated.
Key inputs that shape the totals include diabetes prevalence trends, the share of patients on insulin versus oral and other injectables, average daily dose or prescription intensity proxies, CGM and SMBG testing patterns, insulin pump and pen utilization, and replacement or replenishment cycles for sensors and consumables. Price points are built from a mix of public reimbursement cues and interview based net price ranges, and gaps are handled by using conservative midpoint assumptions that are rechecked with channel participants.
Forecasts are built using scenario analysis, since policy changes (such as subsidy expansions) and technology mix shifts can change adoption faster than a straight line trend. The final outlook is corroborated with selective bottom-up checks, such as sampled ASP x volume for high value device categories and supplier revenue reasonableness checks, which helps adjust the aggregate if any category appears overstated.
Data Validation & Update Cycle
Validation is done through triangulation across independent signals so the model does not rely on one data series or one interview view. We run variance checks across category totals, look for breaks versus known reimbursement events, and review per patient spend outputs to confirm they stay realistic for Australia.
Before sign-off, the work goes through multi step analyst reviews, and re-contacts are triggered when an assumption moves the market materially or when new policy or pricing information appears. Reports are refreshed annually, and interim updates are made when a major product launch, guideline shift, or reimbursement change affects demand. Right before delivery, a fresh pass is completed so clients receive the latest updated view.
Mordor Intelligence's Australia Diabetes Care Drugs and Devices Market Size Versus Other Published Estimates
Published market sizes for diabetes care in Australia often do not match, even when the headlines look similar, because the underlying scope and counting logic can differ in everyday ways. Differences usually come from whether the estimate is devices only versus drugs plus devices, how subsidized volumes are translated into value, and whether forecasts assume steady pricing or a faster mix shift to premium technologies.
Weight loss therapies used mainly for obesity sit outside Mordor Intelligence's scope here, and the model stays focused on diabetes indicated drugs plus monitoring and management devices, which avoids inflating totals when GLP-1 demand is driven by non-diabetes use. Some other figures also treat CGM growth as a straight device shipment story, while our interviews put more emphasis on subsidy eligibility, sensor replacement cadence, and switching behavior, which can change the value curve year to year.
Benchmark comparison
| Source | Market Size | Gaps in Research Methodology |
|---|---|---|
| Mordor Intelligence | USD 1.56 B (2025) | |
| Trade Publisher A | USD 0.58 B (2023) | Devices-only framing is used, and the number is anchored to an earlier base year, which typically excludes prescription drug value and misses the step-up from broader CGM funding periods. |
| Industry Commentary B | USD 2.10 B (2026) | A wider diabetes spending lens is implied, which can blend drugs, devices, and adjacent metabolic care, and it is also reported in a future year that bakes in a more aggressive adoption scenario. |
The spread in the table mainly comes from scope and timing, not from a single arithmetic error. When the market is defined as drugs plus core diabetes devices in a single base year, the result stays easier to reconcile to treated cohorts, therapy intensity, and replenishment cycles, which is why this estimate is more traceable for planning.
Key Questions Answered in the Report
What is the current undefined size?
The undefined is projected to register a CAGR of 9.08% during the forecast period (2026-2031)
Who are the key players in undefined?
Medtronics, Roche, NovoNordisk, Sanofi and Omnipod are the major companies operating in the undefined.
What years does this undefined cover?
The report covers the undefined historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the undefined size for years: 2026, 2027, 2028, 2029, 2030 and 2031.
Page last updated on:
